NCT06515314 - HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

August 10, 2026

Study Completion Date

August 10, 2027

Conditions

Hepatic Cell Carcinoma

Interventions

BIOLOGICAL

AFP Specific T Cell Receptor T Cells

"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"

Trial Locations (1)

Unknown

RECRUITING

Zhongshan Hospital Affiliated to Fudan University, Shanghai